Free Trial

Ligand Pharmaceuticals (LGND) SEC Filings & 10K Form

$86.40
+1.49 (+1.75%)
(As of 05/24/2024 ET)

Recent Ligand Pharmaceuticals SEC Filings

DateFilerForm TypeView
05/17/2024
6:59 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/17/2024
7:00 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/17/2024
4:45 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/16/2024
4:39 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2024
6:34 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2024
5:01 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2024
1:45 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144/A
05/14/2024
6:42 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/13/2024
5:14 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/13/2024
4:32 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2024
5:03 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/09/2024
5:06 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/09/2024
3:11 PM
Ligand Pharmaceuticals (Filer)
Form DEFA14A
05/07/2024
6:36 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
5:07 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/26/2024
5:35 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2024
4:47 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2024
12:27 PM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
4:28 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2024
5:12 PM
Ligand Pharmaceuticals (Subject)
Sabba Stephen L (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/29/2024
5:49 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:50 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:50 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:50 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
3:49 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144/A
02/29/2024
3:16 PM
Ligand Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/28/2024
5:05 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/28/2024
4:43 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/27/2024
6:24 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/16/2024
7:10 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2024
5:26 AM
Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
Form SC 13G
02/13/2024
2:39 PM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
02/12/2024
6:42 PM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G
01/22/2024
1:03 PM
BlackRock Inc. (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
01/04/2024
3:07 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:07 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
2:27 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
2:27 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
Tech GIANT’s Plans to Revolutionize Crypto… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.
12/01/2023
7:25 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/18/2023
8:03 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2023
3:36 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2023
7:38 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2023
3:41 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2023
5:12 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/25/2023
3:44 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2023
4:26 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2023
3:20 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2023
5:42 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2023
5:42 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
8:28 AM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:52 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:53 PM
Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:54 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:54 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:55 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:55 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:LGND) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners